Considering a reasonable WTP threshold , intermediate dose statin therapy is economically attractive , and should be a priority intervention in prevention of cardiovascular events in Brazil
BACKGROUND Statins have proven efficacy in the reduction of cardiovascular events , but the financial impact of its widespread use can be substantial .
OBJECTIVE To conduct a cost-effectiveness analysis of three statin dosing schemes in the Brazilian Unified National Health System ( SUS ) perspective .
Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.
OBJECTIVE To assess the cost-effectiveness of rosuvastatin in the treatment of hypercholesterolemia and the prevention of ischemic heart disease ( IHD ) in Portugal . METHODS A probabilistic Markov model was constructed to analyze the costs and consequences of lifetime treatment with rosuvastatin , atorvastatin , pravastatin , and simvastatin . For this purpose , the results from r and omized head-to-head trials evaluating low-density lipoprotein ( LDL ) changes were combined with the results from a meta- analysis defining the relationship between LDL levels and fatal and nonfatal IHD events . The incidence of myocardial infa rct ion ( MI ) was derived from a 9-year Portuguese observational study . The eligible population was defined as untreated individuals aged more than 35 years with LDL levels above 115 mg/dl .  Death rates due to IHD and other causes were obtained from official data . Re source use in the treatment of MI was estimated by a Delphi panel of eight Portuguese cardiologists with at least 15 years of clinical practice . Costs were calculated from the payers ' perspective . RESULTS Rosuvastatin  increases life expectancy between 5.5 and 12.1 days per patient . It is cost-saving when compared to atorvastatin , but it increases costs when assessed against pravastatin and simvastatin ( euro1,004 and euro684 per patient , respectively ) . Therefore , rosuvastatin is a dominant alternative compared to atorvastatin , having an incremental cost-effectiveness ratio of euro30,350 to pravastatin and euro39,340 to simvastatin . In the probabilistic sensitivity analysis , performed rosuvastatin always dominates atorvastatin and is associated with a cost per life-year gained inferior to euro50,000 in 95.7 % of the cases when compared to pravastatin and in 67.0 % simulations when assessed against simvastatin . CONCLUSIONS Rosuvastatin is a cost-effective alternative in the prevention of IHD in Portugal
Considering a reasonable WTP threshold , intermediate dose statin therapy is economically attractive , and should be a priority intervention in prevention of cardiovascular events in Brazil
BACKGROUND Statins have proven efficacy in the reduction of cardiovascular events , but the financial impact of its widespread use can be substantial .
OBJECTIVE To conduct a cost-effectiveness analysis of three statin dosing schemes in the Brazilian Unified National Health System ( SUS ) perspective .